Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Syngene International Ltd.

Division of Biocon Ltd.
www.syngeneintl.com

Latest From Syngene International Ltd.

Zydus Cadila Plans Indian Remdesivir Entry In July

Zydus Cadila hopes to launch its version of Gilead’s remdesivir by end-July in India, even as earlier licensees Hetero Drugs and Cipla have just commercialized the antiviral. Plans for pegylated interferon alfa-2b to treat COVID-19 include a trial in Mexico and an IND in the US. Separately, desidustat is being considered for additional indications.

Strategy Generic Drugs

Remdesivir Rivals Hit Indian Market

Gilead licensees Hetero and Cipla introduce remdesivir, the antiviral seen as a potential treatment for COVID-19, in India. Pricing plans will be closely watched and supplies in the country are expected to stabilize soon, possibly turning to a surplus situation in several months.

Coronavirus COVID-19 Generic Drugs

Is Dexamethasone The Next Hydroxychloroquine For India?

While the jury is still out on dexamethasone being the new hero in the fight against COVID-19 after the hype around hydroxychloroquine has died down, Indian pharma is watching developments closely. Gains of companies like Zydus Cadila, Wockhardt, Cadila and Cipla in the domestic market will be constrained by price caps while any increase in exports will depend on emergency use authorizations.

Coronavirus COVID-19 India

Biocon Biologics Gets True North Investment

Private equity group True North continues to back the Biocon group and is picking up a minority stake in Biocon Biologics in a deal that values the subsidiary at $3bn. Separately, another subsidiary, Biocon Biosphere, has also been set up as part of efforts to unlock the full potential of the business.

Deals Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Syngene International Pvt. Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • India
  • Parent & Subsidiaries
  • Biocon Ltd.
  • Senior Management
  • Jonathan Hunt, CEO
    M.B. Chinappa, Pres., Fin. & CFO
    Manoj Nerurkar, PhD, COO
  • Contact Info
  • Syngene International Ltd.
    Phone: (91)
    Bommasandra-Jigani Link Rd., Biocon Park
    Bangalore, 560 099
    India
UsernamePublicRestriction

Register